Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

No longer available × Recurrence × sugemalimab × Clear all

Status

No longer available 1

Sponsor Class

Study Type

Expanded_access 1

Sponsor

Cancer Type

Conditions

Recurrence 1 Lymphoma, Extranodal NK-T-Cell 1

Interventions

zanubrutinib 1 sugemalimab 1 revumenib 1 loncastuximab tesirine 1 fludarabine phosphate 1 denileukin diftitox 1 Whole-Body Irradiation 1 Tacrolimus 1 Panobinostat 1 Mycophenolic Acid 1 Cytarabine 1 Cord Blood Stem Cell Transplantation 1 Busulfan 1 Bortezomib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05131438 2023-03-27

An Expanded Access Program to Provide Sugemalimab for the Treatment of Relapsed or Refractory Extranodal Natural Killer/T-Cell Lymphoma (R/R ENKTL)

EQRx International, Inc.

No longer available

Recurrence, Lymphoma, Extranodal NK-T-Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡